Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Amicus Therapeutics (FOLD) over the last 17 years, with Q3 2025 value amounting to $17.3 million.

  • Amicus Therapeutics' Net Income towards Common Stockholders rose 35718.53% to $17.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$14.1 million, marking a year-over-year increase of 8656.87%. This contributed to the annual value of -$56.1 million for FY2024, which is 6298.69% up from last year.
  • Latest data reveals that Amicus Therapeutics reported Net Income towards Common Stockholders of $17.3 million as of Q3 2025, which was up 35718.53% from -$24.4 million recorded in Q2 2025.
  • In the past 5 years, Amicus Therapeutics' Net Income towards Common Stockholders ranged from a high of $17.3 million in Q3 2025 and a low of -$85.3 million during Q1 2022
  • Moreover, its 5-year median value for Net Income towards Common Stockholders was -$43.2 million (2023), whereas its average is -$38.1 million.
  • Within the past 5 years, the most significant YoY rise in Amicus Therapeutics' Net Income towards Common Stockholders was 35718.53% (2025), while the steepest drop was 5557.11% (2025).
  • Quarter analysis of 5 years shows Amicus Therapeutics' Net Income towards Common Stockholders stood at -$83.3 million in 2021, then skyrocketed by 32.92% to -$55.9 million in 2022, then surged by 39.42% to -$33.8 million in 2023, then soared by 143.55% to $14.7 million in 2024, then rose by 17.42% to $17.3 million in 2025.
  • Its Net Income towards Common Stockholders was $17.3 million in Q3 2025, compared to -$24.4 million in Q2 2025 and -$21.7 million in Q1 2025.